0001209191-24-002391.txt : 20240129
0001209191-24-002391.hdr.sgml : 20240129
20240129185207
ACCESSION NUMBER: 0001209191-24-002391
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240125
FILED AS OF DATE: 20240129
DATE AS OF CHANGE: 20240129
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Larson Tina Marriott
CENTRAL INDEX KEY: 0001856414
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-40323
FILM NUMBER: 24575329
MAIL ADDRESS:
STREET 1: C/O RECURSION PHARMACEUTICALS
STREET 2: 41 S. RIO GRANDE STREET
CITY: SALT LAKE CITY
STATE: UT
ZIP: 84101
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: RECURSION PHARMACEUTICALS, INC.
CENTRAL INDEX KEY: 0001601830
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 464099738
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 41S RIO GRANDE STREET
CITY: SALT LAKE CITY
STATE: UT
ZIP: 84101
BUSINESS PHONE: (385) 269-0203
MAIL ADDRESS:
STREET 1: 41S RIO GRANDE STREET
CITY: SALT LAKE CITY
STATE: UT
ZIP: 84101
FORMER COMPANY:
FORMER CONFORMED NAME: Recursion Pharmaceuticals, LLC
DATE OF NAME CHANGE: 20140305
4
1
doc4.xml
FORM 4 SUBMISSION
X0508
4
2024-01-25
0
0001601830
RECURSION PHARMACEUTICALS, INC.
RXRX
0001856414
Larson Tina Marriott
41 S. RIO GRANDE STREET
SALT LAKE CITY
UT
84101
0
1
0
0
President and COO
1
Class A Common Stock
2024-01-25
4
M
0
8000
1.06
A
422584
D
Class A Common Stock
2024-01-25
4
S
0
8000
10.3452
D
414548
D
Stock Option (Right to Buy)
8.55
2033-02-01
Class A Common Stock
0
434122
D
Stock Option (Right to Buy)
1.06
2024-01-25
4
M
0
8000
0.00
D
2028-07-22
Class A Common Stock
8000
504000
D
Stock Option (Right to Buy)
11.40
2032-02-04
Class A Common Stock
0
159226
D
Stock Option (Right to Buy)
11.40
2022-02-04
2032-02-04
Class A Common Stock
0
4784
D
Stock Option (Right to Buy)
2.48
2030-12-30
Class A Common Stock
0
150000
D
Transaction is pursuant to a 10b5-1 trading plan established by the Reporting Person dated March 1, 2023.
The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from $10.17 to $10.54 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request.
The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2023, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter.
Twenty-Five percent (25%) of the shares subject to the award (the stock option grant was for a total of 765,000 shares prior to exercise) shall vest one year after July 16, 2018, or the Annual Vesting Commencement Date, and one-forty-eighth (1/48th) of the shares subject to the award shall vest each month thereafter on the same day of the month as the Annual Vesting Commencement Date.
The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2022, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter.
One forty-eighth (1/48th) of the shares subject to the award shall vest one month after December 31, 2020, or the Monthly Vesting Commencement Date, and one forty-eighth (1/48th) of the shares subject to the award shall vest each month thereafter on the same day of the month as the Monthly Vesting Commencement Date.
/s/ Jonathan Golightly, attorney-in-fact
2024-01-29